With debilitating symptoms including tremor, slow movement, rigidness and pain, Parkinson’s disease remains one of the most feared neurodegenerative conditions. DDW’s Megan Thomas reports on the latest clinical progress as pharma and biotech search for new therapies for this currently incurable condition. Parkinson’s is the most common movement disorder, affecting… Read More
A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials. BlueRock Therapeutics, a subsidiary of Bayer, has announced details of the positive data from a Phase I clinical trial for bemdaneprocel (BRT-DA01). The data were presented at… Read More
Bayer subsidiary BlueRock Therapeutics, and bit.bio have announced a collaboration to discover and manufacture regulatory T cell (Treg) based therapies. Under the terms of the agreement, bit.bio will use its machine learning discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs. Read More
